- Home
- GRVY vs CTNM Comparison
GRVY vs CTNM Comparison
Compare GRVY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRVY | CTNM |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.5M | 489.4M |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GRVY | CTNM |
|---|---|---|
| Price | $56.81 | $12.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 63.3K | ★ 175.1K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.54 | $3.57 |
| 52 Week High | $74.75 | $16.33 |
Technical Indicators
Market Signals| Indicator | GRVY | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.20 | 47.44 |
| Support Level | $55.89 | $11.62 |
| Resistance Level | $59.64 | $13.26 |
| Average True Range (ATR) | 2.36 | 0.80 |
| MACD | -0.57 | -0.00 |
| Stochastic Oscillator | 9.06 | 53.28 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.